Gene · 8744
Papers3,166
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,021 to 1,040 of 3,166
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Deoxynivalenol triggers porcine intestinal tight junction disorder through hijacking SLC5A1 and PGC1α-mediated mitochondrial function. | Food Chem Toxicol | 2022 | 35307453 | PubTator, text mining | PubMed |
| Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells. | Signal Transduct Target Ther | 2022 | 35301282 | PubTator, text mining | PubMed |
| Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases. | Cell Death Dis | 2022 | 35301281 | PubTator, text mining | PubMed |
| Development and Validation of a Ferroptosis-Related lncRNAs Prognosis Model in Oral Squamous Cell Carcinoma. | Front Genet | 2022 | 35299954 | PubTator, text mining | PubMed |
| Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors. | Cancer Immunol Immunother | 2022 | 35299256 | PubTator, text mining | PubMed |
| Differential effects on natural killer cell production by membrane-bound cytokine stimulations. | Biotechnol Bioeng | 2022 | 35297033 | PubTator, text mining | PubMed |
| CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma. | J Pathol Clin Res | 2022 | 35289116 | PubTator, text mining | PubMed |
| Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. | J Immunother Cancer | 2022 | 35288468 | PubTator, text mining | PubMed |
| T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion. | J Immunother Cancer | 2022 | 35288464 | PubTator, text mining | PubMed |
| DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity. | J Exp Clin Cancer Res | 2022 | 35287686 | PubTator, text mining | PubMed |
| Clinical Roles of Risk Model Based on Differentially Expressed Genes in Mesenchymal Stem Cells in Prognosis and Immunity of Non-small Cell Lung Cancer. | Front Genet | 2022 | 35281822 | PubTator, text mining | PubMed |
| Advances of DNA Damage Repair-Related Drugs and Combination With Immunotherapy in Tumor Treatment. | Front Immunol | 2022 | 35281059 | PubTator, text mining | PubMed |
| Transcriptional Expressions of ALDH1A1/B1 as Independent Indicators for the Survival of Thyroid Cancer Patients. | Front Oncol | 2022 | 35280765 | PubTator, text mining | PubMed |
| Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer. | Int J Mol Sci | 2022 | 35269922 | PubTator, text mining | PubMed |
| The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good. | Cancers (Basel) | 2022 | 35267668 | PubTator, text mining | PubMed |
| Comprehensive Analysis of the Prognosis and Drug Sensitivity of Differentiation-Related lncRNAs in Papillary Thyroid Cancer. | Cancers (Basel) | 2022 | 35267662 | PubTator, text mining | PubMed |
| Managing Osteopetrosis in the Complex Polytrauma Orthopedic Patient. | Cureus | 2022 | 35265418 | PubTator, text mining | PubMed |
| Transcriptome Profiling of Porcine Naïve, Intermediate and Terminally Differentiated CD8+ T Cells. | Front Immunol | 2022 | 35265090 | PubTator, text mining | PubMed |
| The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). | Curr Treat Options Oncol | 2022 | 35258793 | PubTator, text mining | PubMed |
| Infections in the Developing Brain: The Role of the Neuro-Immune Axis. | Front Neurol | 2022 | 35250814 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/papers?page=52